International IP and Small Businesses: Novavax CEO Testifies on BIO's Behalf

Stanley C. Erck, President and CEO of Novavax testified at the USPTO on behalf of BIO to discuss the importance of IP protection internationally for small biotechnology companies.

Paraguay IP Section 306 Monitoring: BIO Comments

BIO urges the United States Trade Representative to continue to address the persistent deficiencies in patent protection and data protection regimes in Paraguay.  These deficiencies raise issues in respect to Paraguay's bilateral and international obligations and deny adequate and effective protection for the intellectual property rights of BIO's members.

BIO Commends Department of Commerce for Promoting Robust Intellectual Property Standards and Policies Abroad

BIO joined the Pharmaceutical Research and Manufacturers of America (PhRMA) in a letter commending Department of Commerce Secretary Gary Locke for his leadership in promoting robust intellectual property standards and policies. The letter commends the United States Patent Office (PTO) for their engagement at the World Intellectual Property Organization (WIPO) resisting calls to commence negotiations on ill-advised and harmful changes to the global patent system relating to "genetic resources" and "traditional knowledge."

Scientific American’s Worldview 2011 Preview

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.

BIO Urges U.S. Trade Representative to Preserve IP Protection Abroad

The Biotechnology Industry Organization (BIO) stresses the critical importance of protecting intellectual property abroad in comments recently filed with the U.S. Trade Representative (USTR) on the 2011 Special 301 Review.

2011 Special 301: BIO Comments to USTR

In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor.

Intellectual Property in Emerging Markets

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

BIO comments on the proposed accession of Malaysia to the Trans Pacific Partnership (TPP) negotiations

Parties to the TPP negotiation are a mixture of countries that actively cultivate and import GE crops, as well as those that have yet to develop functioning regulatory systems. Therefore, the TPP offers the potential to achieve a common regulatory approach and disciplines for agricultural biotechnology.

Biological Diversity: Draft Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity

The Heads of Biotechnology Associations: Asia, Europe and the Americas and their members support the agreed objective of the Protocol and the greater goal to establish a practical and workable international regime governing access to genetic resources and the fair and equitable sharing of benefits arising from these resources.

Intellectual Property: Compulsory Licenses Published by the Department of Industrial Policy and Promotion within India's Ministry of Commerce and Industry

BIO is disappointed to see the recent DIPP’s discussion paper on compulsory licensing of biopharmaceuticals, which sends a deeply troubling message to investors and collaborators at a time when the industry and the Government of India are seeking to increase investment, collaboration, and innovation in the biotech sector.